Background Several clinical trials of dapagliflozin in patients with type 2 diabetes mellitus
(T2DM) at elevated cardiovascular risk have observed reduced hospitalization for heart …

Background: Heart failure (HF) is a major cause of recurrent hospitalization and death
worldwide. Sodium-glucose cotransporter-2 inhibitors including dapagliflozin are anti …

Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent newly developed oral
antidiabetic drugs that are practiced for type 2 diabetes mellitus management and may …

Background Cardiovascular disease threatens the health and quality of life of individuals,
particularly those with type II diabetes. Recently, some studies have reported the effect of …

Aim We investigated the efficacy and safety of dapagliflozin, a sodium–glucose
cotransporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) and heart failure …

Background: In patients with heart failure (HF) and reduced ejection fraction (HFrEF) with or
without type 2 diabetes mellitus, the sodium-glucose cotransporter 2 inhibitor (SGLT2i) …

Heart failure (HF) is a substantial source of morbidity and mortality. Several clinical trials
have reported a significant HF benefit of sodium/glucose cotransporter 2 (SGLT2) inhibitors …

Abstract Treatment of patients with heart failure and reduced left ventricular ejection fraction
(HFrEF) aims to reduce mortality, prevent rehospitalizations due to heart failure (HF) …

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …